Categories: Awards

OncoStem Diagnostics Wins CII’s Startupreneur Award in Biotech and Pharma Category

Bangalore, September 05, 2020: OncoStem Diagnostics, an Oncology focused company that enables personalised cancer treatment has won the Startupreneur Award organized by CII (Confederation of Indian Industry) in the Biotech and Pharma Category, for its innovative prognostic test ‘CanAssist Breast’.

CII’s Startupreneur awards was started with an aim to recognise startups for excellence in cutting-edge technology and innovation, wealth creation, and employment generation. In 2018, CII put into action its novel concept of providing the essential ‘Corporate Connect’ to start-ups. The concept is based on the premise that when a large corporate house adopts a start-up which is working in its own area or allied areas of business, then it results in a win-win for both. These awards provide the most prestigious recognition from the corporate world to the most promising start-ups in India in various sectors.

Video Linkyoutu.be/DgtVBk1bH8o.

Speaking about the award, Dr. Manjiri Bakre, CEO and Founder, OncoStem Diagnostics said, “It’s a great honour to receive this award and to be recognised for our innovation. This award gives us a valuable opportunity to collaborate with established corporates in the field of our work and leverage their network to ensure that our test is accessible to a larger audience.”

OncoStem’s CanAssist Breast is a prognostic test for early-stage hormone receptor positive breast cancer patients. It makes customized treatment possible by analysing the patients tumor in depth and providing a patient specific report. CanAssist Breast categorizes patients based on the risk of cancer recurrence clearly as either ‘low or high’ with no grey area in between. This clear distinction of patients based on risk of cancer recurrence allows doctors to devise treatment plans that are in tune with the prognosis, maintaining a balance between the benefits and side effects. Patients who are at low risk of relapse can potentially avoid chemotherapy and its associated side-effects while patients who are at high risk of relapse would benefit from the addition of chemotherapy to their treatment regimen.

The award from CII is yet another feather in OncoStem’s cap. CanAssist Breast was also awarded the ‘Best Innovation – Cancer Risk Assessment’ by NASSCOM’s CoE’s (Centre of Excellence) Life Sciences and healthcare innovation forum (LHIF) last year.

Newsvoir

The Pharma Times News Bureau

Recent Posts

Lung Cancer in India: Understanding Risk Factors and the Importance of Early Detection

By Dr. Pavan Yadav, Lead Consultant - Interventional Pulmonology & Lung Transplantation, Aster RV Hospital.…

14 hours ago

10 Winter Skin Care Tips Dermatologists Swear By

Dr. Priyanka Kuri, Consultant - Dermatology, Aster Whitefield Hospital, Bengaluru  Winter weather brings a host…

3 days ago

Fighting Viral Hepatitis in India: Prevention, Risks, and the Path to Better Health

By Dr. Naveen Ganjoo, Senior Consultant - Hepatology & Integrated Liver Care, Aster RV Hospital…

4 days ago

Hon’ble Prime Minister Shri Narendra Modi Inaugurates LyfiusPharma’s Flagship Penicillin-G Facility at Kakinada, Andhra Pradesh

Under the Production Linked Incentive(PLI)scheme, Lyfius Pharma Private Limited(LyfiusPharma) invested ₹2,500 crores in Penicillin-G( Pen-G)facility…

5 days ago

SpOvum® Launches ARTGPT Redefining Patient Support in Assisted Reproductive Technology (ART)

Launched for 1st time in India, ARTGPT is designed to address queries regarding A.R.T treatments Product created…

1 week ago